Mirum Pharmaceuticals’ (MIRM) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report published on Wednesday,Benzinga reports. The firm currently has a $66.00 price target on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q3 2025 earnings at $0.35 EPS and Q4 2025 earnings at $0.61 EPS.

MIRM has been the topic of several other reports. Citigroup increased their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday. Cantor Fitzgerald upped their target price on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Evercore ISI lifted their price target on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Finally, Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $57.73.

Mirum Pharmaceuticals Price Performance

MIRM opened at $43.92 on Wednesday. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of -21.74 and a beta of 1.16. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. The stock’s 50-day moving average price is $39.96 and its 200 day moving average price is $35.79. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $45.81.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 40.98%. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same quarter last year, the firm posted ($0.57) earnings per share. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. As a group, sell-side analysts expect that Mirum Pharmaceuticals will post -1.84 earnings per share for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Quest Partners LLC boosted its position in shares of Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after purchasing an additional 1,127 shares during the period. Amalgamated Bank raised its position in Mirum Pharmaceuticals by 60.8% in the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the period. ProShare Advisors LLC purchased a new position in Mirum Pharmaceuticals during the 2nd quarter worth $213,000. Finally, Creative Planning purchased a new position in Mirum Pharmaceuticals during the 3rd quarter worth $249,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.